PDCD1 and Miyoshi myopathy: A phase II study (NCT02289222) combining the anti-PD-1 pembrolizumab with pomalidomide and low-dose dexamethasone in 48 patients with relapsed/refractory MM resulted in an objective response of 60% including stringent complete response/complete response (8%), very good partial response (19%), and partial response (33%), with a median duration of response of 14.7 months (147).